• Search
  • Advanced Search

Search

  • HOME
  • Search
Review Article
Hematology
Promising role of voxelotor in managing sickle cell disease in children: a narrative review
Amit Agrawal, Gaurav Jadon, Japna Singh, Dalwinder Janjua
Clin Exp Pediatr. 2025;68(2):106-114.   Published online November 13, 2024
Voxelotor has promising ability to increase hemoglobin levels and reduce hemolysis markers in patients with sickle cell disease (SCD). Several preclinical and phase II/III trials have demonstrated its efficacy, dose-dependent responses, and tolerability in children. Ongoing trials are assessing its safety and effectiveness in various populations, including children younger than 12 years. These findings suggest its potential as a disease-modifying drug, warranting further exploration of its role in SCD management.
Original Article
Neonatology (Perinatology)
Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures
Jae Won Shin, Yun Seob Jung, Kyungsoo Park, Soon Min Lee, Ho Seon Eun, Min Soo Park, Kook In Park, Ran Namgung
Clin Exp Pediatr. 2017;60(2):50-54.   Published online February 27, 2017
Purpose

The aims of this study were to evaluate the safety and pharmacokinetics of levetiracetam (LEV) in neonates with seizures and to establish a population pharmacokinetics (PPK) model by using the software NONMEM.

Methods

A retrospective analysis of 18 neonatal patients with seizures, who were treated with LEV, including 151 serum samples, was performed. The mean loading dose was 20 mg/kg, followed by...

The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia
Sang Bum Kim, Jang Hoon Lee, Juyoung Lee, Seung Han Shin, Ho Sun Eun, Soon Min Lee, Jin A Sohn, Han Suk Kim, Byung Min Choi, Min Soo Park, Kook In Park, Ran Namgung, Moon Sung Park
Clin Exp Pediatr. 2015;58(9):347-353.   Published online September 21, 2015
Purpose

The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD).

Methods

The Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA)....

Erratum
Tacrolimus versus Cyclosporine Immunosuppression in Pediatric Renal Transplantation : Pharmacokinetic Consideration
Jung Sue Kim
Clin Exp Pediatr. 2005;48(5):476-480.   Published online May 15, 2005
Immunosuppressive therapy in pediatric renal transplant recipients is changing consequence of the increasing number of available immunosuppressive agents. The optimal use of immunosuppressive agents requires a thorough understanding of the pharmacokinetic characteristics, but the information on the pharmacokinetic characteristics of these drugs in pediatric transplant recipients is still limited. In general, patients younger than 5 years old show higher clearance...
Original Article
Pharmacokinetics of Cyclosporine A and Its Therapeutic Effect in Children with Renal Diseases
Woo Sung Chun, Min-Soo Park, Jae Seung Lee, Juyun Yu, Moon Sung Park, Ki-Soo Pa
Clin Exp Pediatr. 2004;47(2):193-203.   Published online February 15, 2004
Purpose : To know the body handling properties and anti-proteinuric effect of cyclosporine A(CsA) in children with renal diseases, 34 patients with nephrotic syndrome or glomerular diseases were included to treatment trials and evaluated. Methods : Microemulsion formula CsA, 5 mg/kg/day was administered orally in two divided doses for 9.3?.6 months. Pharmacokinetic studies of CsA were done twice at beginning and...
Pharmacokinetics of Gentamicin and Amikacin in Korean Children with Normal Renal Function
Jin Young Park, Ktung Bae Kwon, Mee Ran Kim, Hoan Jong Lee, Jin Q Kim, Wan Gyoon Shim, Kyoung Ho Park, Hae Lim Chung
Clin Exp Pediatr. 1994;37(2):185-192.   Published online February 15, 1994
We analysed retrospectively pharmacokinetic parameters of gentamicin and amikacin in 44 and 58 Korean pediatric patients, respectively, with normal renal function. Pharmacokinetic parameters were calculated from two concentrations in serum by method of Sawchuck. There was wide individual variation in peak serum concentrations of gentamicin and amikacin. Administration of the usually recommended doses yielded subtherapeutic concentration in 47% and 82%,...
The Pharmacokinetics and Biological Effects of Yeat Dervied Recombinant Methionyl Growth Hormone in growth Hormone Deficient Children
Byung Churl Lee
Clin Exp Pediatr. 1992;35(3):349-354.   Published online March 15, 1992
The parmacokinetics and biological effects of an recombinant methionyl growth hormone(LBD-003) produced by the expression of genomic hGH in a yeast cell line, were studied in growth hormone deficient children. Twelve patients were randomly assigned to two age-matched subcutaneous and intramuscular groups. Each group consists of 6 patients. Each subject received an dosage of 0.1 U hGH(LBD-003)/kg, BW, Blood was drawn before...
TOPICS

Browse all articles >

ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
ABOUT
Editorial Office
Korean Pediatric Society
#1606 Seocho World Officetel, 19 Seoun-ro, Seocho-ku, Seoul 06732, Korea
Tel: +82-2-3473-7306    Fax: +82-2-3473-7307    E-mail: office@e-cep.org                

Clinical and Experimental Pediatrics is an open access journal. All articles are distributed under the terms of the Creative Commons Attribution NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/)

Copyright © 2025 by Korean Pediatric Society.      Developed in M2PI